We are live on
!
Find out more
APUS
Apimeds Pharmaceuticals US
APUS
APUS
8 hedge funds and large institutions have $712K invested in Apimeds Pharmaceuticals US in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
45% more capital invested
Capital invested by funds: $490K → $712K (+$222K)
33% more funds holding
Funds holding: 6 → 8 (+2)
0.08% more ownership
Funds ownership: 0.24% → 0.32% (+0.08%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Holders
8
Holders Change
+2
Holders Change %
+33.33%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
6
Increased
–
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
Top Sellers
| 1 |
YAG
Yorkville Advisors Global
Mountainside,
New Jersey
|
-$440K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$23.5K |
| 3 |
Goldman Sachs
New York
|
-$21.1K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.55K |